Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma

Trial Profile

Open-Label, Multi-Center, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 (Mogamulizumab) Versus Vorinostat in Subjects With Previously Treated Cutaneous T-Cell Lymphoma

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Dec 2017

At a glance

  • Drugs Mogamulizumab (Primary) ; Vorinostat
  • Indications Cutaneous T cell lymphoma; Mycosis fungoides; Sezary syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms MAVORIC
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 11 Dec 2017 Results published in the a Kyowa Hakko Kirin media release.
    • 11 Dec 2017 According to a Kyowa Hakko Kirin media release, results from this trial will be presented at the Annual Meeting of American Society of Hematology (2017).
    • 30 Nov 2017 According to a Kyowa Hakko Kirin media release, the company announced the submission of a supplemental application to remove the requirement for pre-treatment diagnostic testing and change the dosage and administration in patients with relapsed or refractory cutaneous T-cell lymphoma (CTCL) for mogamulizumab to the Ministry of Health, Labor and Welfare in Japan, based on data from this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top